Andrew M  Davis
Andrew M Davis
AstraZeneca, Fisons, Astra, University of Kent
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
Is there a difference between leads and drugs? A historical perspective
TI Oprea, AM Davis, SJ Teague, PD Leeson
Journal of chemical information and computer sciences 41 (5), 1308-1315, 2001
8702001
The design of leadlike combinatorial libraries
SJ Teague, AM Davis, PD Leeson, T Oprea
Angewandte Chemie International Edition 38 (24), 3743-3748, 1999
7391999
A comparison of physiochemical property profiles of development and marketed oral drugs
MC Wenlock, RP Austin, P Barton, AM Davis, PD Leeson
Journal of medicinal chemistry 46 (7), 1250-1256, 2003
5202003
Application and limitations of X‐ray crystallographic data in structure‐based ligand and drug design
AM Davis, SJ Teague, GJ Kleywegt
Angewandte Chemie International Edition 42 (24), 2718-2736, 2003
4322003
Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis
AM Davis, SJ Teague
Angewandte Chemie International Edition 38 (6), 736-749, 1999
4031999
Time-related differences in the physical property profiles of oral drugs
PD Leeson, AM Davis
Journal of medicinal chemistry 47 (25), 6338-6348, 2004
2592004
Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles
RP Austin, AM Davis, CN Manners
Journal of pharmaceutical sciences 84 (10), 1180-1183, 1995
1911995
Chemical predictive modelling to improve compound quality
JG Cumming, AM Davis, S Muresan, M Haeberlein, H Chen
Nature reviews Drug discovery 12 (12), 948-962, 2013
1652013
Limitations and lessons in the use of X-ray structural information in drug design
AM Davis, SA St-Gallay, GJ Kleywegt
Drug Discovery Today 13 (19), 831, 2008
1602008
Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT
MH Bridgland-Taylor, AC Hargreaves, A Easter, A Orme, DC Henthorn, ...
Journal of pharmacological and toxicological methods 54 (2), 189-199, 2006
1522006
Components of successful lead generation
AM Davis, DJ Keeling, J Steele, NP Tomkinson, AC Tinker
Current topics in medicinal chemistry 5 (4), 421-439, 2005
1072005
Charge description of base-catalyzed alcoholysis of aryl phosphodiesters: A ribonuclease model
AM Davis, AD Hall, A Williams
Journal of the American Chemical Society 110 (15), 5105-5108, 1988
1071988
A single transition state in the reaction of aryl diphenylphosphinate esters with phenolate ions in aqueous solution
N Bourne, E Chrystiuk, AM Davis, A Williams
Journal of the American Chemical Society 110 (6), 1890-1895, 1988
1031988
Next Gen: transforming the UK into the world's leading talent hub for the video games and visual effects industries
I Livingstone, A Hope
Nesta, 2010
852010
A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries
KK Chohan, SW Paine, J Mistry, P Barton, AM Davis
Journal of medicinal chemistry 48 (16), 5154-5161, 2005
832005
Predictive ADMET studies, the challenges and the opportunities
AM Davis, RJ Riley
Current opinion in chemical biology 8 (4), 378-386, 2004
822004
In Silico Human and Rat Vss Quantitative Structure−Activity Relationship Models
MP Gleeson, NJ Waters, SW Paine, AM Davis
Journal of medicinal chemistry 49 (6), 1953-1963, 2006
812006
Drug-like properties: guiding principles for design–or chemical prejudice?
PD Leeson, AM Davis, J Steele
Drug Discovery Today: Technologies 1 (3), 189-195, 2004
792004
An alternative method for the evaluation of docking performance: RSR vs RMSD
D Yusuf, AM Davis, GJ Kleywegt, S Schmitt
Journal of chemical information and modeling 48 (7), 1411-1422, 2008
742008
Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients
P Barton, AM Davis, PJH Webborn, DJ McCarthy
Journal of pharmaceutical sciences 86 (9), 1034-1039, 1997
721997
The system can't perform the operation now. Try again later.
Articles 1–20